Johan Lund

Celgene Corp. is an integrated global biopharmaceutical company, which engages in the discovery, development and commercialization of therapies for the treatment of cancer and inflammatory diseases. Its primary commercial stage products include Revlimid, Pomalyst, Imnovid, Otezla, Abraxane, and Vidaza. The company was founded by David Stirling and Sol Barer in 1986 and is headquartered in Summit, NJ.

AstraZeneca AB engages in biopharmaceutical business. It provides treatment of diseases in cardiovascular and metabolic diseases, cancer, respiratory, inflammation, and autoimmunity. The firm offers operations in the areas of infection, neuroscience, and stomach and intestinal diseases. The company was founded in 1999 and is headquartered in Sodertalje, Sweden.

Aqilion AB is a venture capital firm. The firm was founded in 2002 by Jan Ekberg and Mats G. Ringesten. It's headquartered in Helsingborg, Sweden.

Genagon Therapeutics AB engages in the provision of scientific and technical research and development services. It develops and commercializes pharmaceuticals and medical products. The company was founded by Johan Erik Simon Fredriksson and Olof Andries Blokzijl on June 5, 2015 and is headquartered in Stockholm, Sweden.

Pelago Bioscience AB is a specialized CRO that focuses on their patented cetsa® technology. The private company is based in Solna, Sweden. The technology can be applied throughout all steps of the drug discovery value chain. Pelago Bioscience provides bespoke projects in a wide range of services. The Swedish company's cetsa® navigate enables rapid target engagement confirmation, cetsa® navigate ht is for efficient high-throughput discovery, and cetsa® explore is a mass spectrometry-based approach allowing unbiased proteome-wide investigation. The Pelago Knowledge Center is a collection of resources used to drive innovation in drug discovery focusing on excellence in target engagement.